A Standard Method for Determining the Minimal Clinically Important Difference for Rehabilitation Measures by Malec, James F. & Ketchum, Jessica M.
Running head: Minimal Clinically Important Difference 
A Standard Method for Determining the Minimal Clinically Important Difference for 
Rehabilitation Measures 
James F. Malec, PhD, FACRM, ABPP-Cn, Rp (Corresponding author) 
Senior Research Professor Emeritus, 
Physical Medicine and Rehabilitation,  
Indiana University School of Medicine  
Emeritus Professor of Psychology, Mayo Clinic 
6722 Meadow Lawn Circle, New Market, MD 21774 
jfmalec@iupui.edu  
Phone: 507-202-5103 
Jessica M. Ketchum, PhD 
Research Department, Craig Hospital, Englewood, CO 
Traumatic Brain Injury Model Systems National Data and Statistical Center, Englewood, CO 




This work was partially supported by Grant Funding for the NIDILRR - Traumatic Brain Injury 
National Data and Statistical Center (90DP0084).  Reprints are not available for this article. The 
authors have no conflicts of interest to declare. 
____________________________________________________
This is the author's manuscript of the article published in final edited form as: 
Malec, J. F., & Ketchum, J. M. (2020). A Standard Method for Determining the Minimal Clinically Important Difference for 
Rehabilitation Measures. Archives of Physical Medicine and Rehabilitation. https://doi.org/10.1016/j.apmr.2019.12.008




A Standard Method for Determining the Minimal Clinically Important Difference for 1 
Rehabilitation Measures 2 
Abstract 3 
 The Minimal Clinically Important Difference (MCID) is receiving increasing interest and 4 
importance in medical practice and research. The MCID is the smallest improvement in scores in 5 
the domain of interest which patients perceive as beneficial. In clinical trials, comparing the 6 
proportion of individuals between treatment and control groups who obtain a MCID may be 7 
more informative than comparisons of mean change between groups since a statistically 8 
significant mean difference does not necessarily represent a difference that is perceived as 9 
meaningful by treatment recipients. The MCID may also be useful in advancing personalized 10 
medicine by characterizing those who are most likely to benefit from a treatment. In clinical 11 
practice, the MCID can be used to identify if a participant is experiencing a meaningful change 12 
in status. 13 
A variety of methods have been used to determine the MCID with no clear agreement on 14 
the most appropriate approach. Two major sets of methods are either (1) distribution-based, i.e., 15 
referencing the MCID to a measure of variability or effect size in the measure of interest, or (2) 16 
anchor-based, i.e., referencing the MCID to an external assessment of change in the condition, 17 
ability, or activity represented by the measure of interest. In prior literature, using multiple 18 
methods to “triangulate” on the value of the MCID has been proposed. In this commentary, we 19 
describe a systematic approach to triangulate on the MCID using both distribution-based and 20 
anchor-based methods. Adaptation of a systematic appro ch for obtaining the MCID in 21 
rehabilitation would facilitate communication and comparison of results among rehabilitation 22 
researchers and providers. 23 
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 36 
The Minimal Clinically Important Difference (MCID) is gaining increasing interest and 37 
importance in medical research and practice. Jaeschk  and colleagues1 originally proposed the 38 
concept in 1989 as “the smallest difference in score in the domain of interest which patients 39 
perceive as beneficial and which would mandate, in the absence of troublesome side effects and 40 
excessive cost, a change in the patient’s management.” As such, use of an anchor-based MCID 41 
as described below epitomizes a marked departure from traditional statistics, such as, 42 
significance testing (p-values) and effect sizes. 43 
Traditionally, studies have estimated and compared th  average improvement (change) in 44 
an outcome measure of interest (MOI) between treatmnt and control groups using statistical 45 
tests to determine if the improvement in the treatment group is “statistically significantly” greater 46 




than that in the control group, beyond what is expected by chance (i.e., p-value < 0.05). 47 
However, statistical significance does not necessarily equate to clinical significance. Large 48 
sample sizes have the power to find that small differences that are not clinically meaningful are 49 
statistically significant, and small samples sizes lack the power to demonstrate that large 50 
differences that are clinically meaningful are statistically significant. 51 
The magnitude of the within-group improvement or the between-group differences in 52 
improvement (relative to the variability at baselin) are often reported as measures of within- and 53 
between-group effect size. For example, Cohen’s d-family effect sizes of 0.2, 0.5, and 0.8 are 54 
commonly interpreted as small, medium, and large effect sizes, respectively. Statistical testing 55 
can be used to answer the question: “Does treatment group improve more than control group 56 
beyond what we would expect by chance?” Effect sizes attempt to extend interpretation beyond 57 
statistical significance towards clinical significance by answering the question: “On average, is 58 
the within group improvement (or between group comparison of improvements) small or large 59 
(relative to the degree of variability across subjects)?” However, this is still an interpretation of 60 
treatment effect at the group level, that is, the av r ge response to treatment across many 61 
individuals, and may not reflect the treatment effect or a particular individual. The degree of 62 
improvement may vary considerably across individuals and may be dependent upon subject-63 
specific characteristics (measured or unmeasured). Furthermore, the effect size is not expressed 64 
in units of the MOI and is not interpretable at theindividual level (e.g., in a clinical setting when 65 
presented with a single patient’s pre- and post-treatm nt values). Finally, and perhaps most 66 
importantly, the effect size may not reflect what the persons served consider a meaningful 67 
difference in their quality of life. 68 




The MCID is expressed in the same units as the MOI and can be more appropriately used 69 
in a clinical setting to identify if a specific individual has had a meaningful response to treatment 70 
when making decisions to continue or alter treatmen. The MCID can also be used in a research 71 
setting and for program evaluation to better understand treatment effect, enabling researchers to 72 
quantify the proportion of people who had a meaningful response to treatment. In addition, this 73 
proportion can be interpreted at the individual level as an estimate of the probability that an 74 
individual will respond to treatment. Statistical significance testing can be used to compare the 75 
proportions of responders, i.e., those achieving a MCID or better, between tr atment and control 76 
groups to determine if the response rate is greater in the treatment group beyond what would be 77 
expected by chance. Additional analyses can be conducte  to describe and compare 78 
characteristics between responders and non-responders to identify subject-specific factors that 79 
are associated with increased or decreased likelihood ( r probability) of response to treatment. 80 
Without a good appreciation of how much improvement is actually meaningful to persons 81 
served, studies may not be appropriately powered to detect clinically meaningful differences. 82 
The MCID can be used to better design studies so that s atistical and clinical significance are 83 
more aligned.  Studies can be powered to have sufficient sample size to detect a meaningful 84 
change rather than a statistically significant difference based on effect sizes. For example, studies 85 
are often powered to detect a Cohen’s d effect size of 0.5 (difference/SD), which could represent 86 
different magnitudes of change depending on the SD. Furthermore, studies are often 87 
underpowered to conduct analyses assessing response to treatment as comparisons of the 88 
proportion of responders between groups and the factors associated with the likelihood of 89 
response often require larger sample sizes than comparisons of mean change. Studies of 90 
treatment efficacy should be adequately powered to have sufficient sample to detect differences 91 




in mean changes between groups as well as differenc in the proportion of responders between 92 
groups in order to maximize understanding of the treatment effect being studied. 93 
Statistical testing, effect size, and MCID each provide researchers and clinicians with 94 
unique information regarding treatment efficacy at the group level. However, the MCID can also 95 
be used specifically at the individual level. It is expressed in the same units as the MOI making it 96 
easily implemented in a clinical setting when considering continuing or altering treatment. 97 
Response to treatment analyses and advances in personalized medicine research can help further 98 
guide clinicians’ treatment selection by identifying subject-specific characteristics associated 99 
with increased or decreased likelihood of treatment r sponse. As we will describe in this paper, 100 
the value of the MCID, like other measures of treatment effect, can be obtained in a statistically 101 
reliable manner but may be substantially different in value from measures of effect size or other 102 
types of distribution-based indicators. 103 
Despite its potential value, computation of the MCID is controversial as a recent 104 
exchange of Letters to the Editor  in the Archives illustrates.2 Two major methods have been 105 
proposed to derive the MCID: a distribution-based approach and an anchor-based approach.3-9 106 
The distribution-based approach references statistical indicators of significant change, such as, 107 
the standard error of measurement (SEM), indicators of various effect sizes, such as, a standard 108 
deviation (SD), or factors of these basic indicators. The anchor-based approach estimates the 109 
MCID in reference to another estimate of meaningful change by the person served or a service 110 
provider. Most commonly, a Global Impression of Change (GIC) rating is used as the anchor. 111 
Within the anchor-based approach, the degree of change in the MOI that indicates meaningful 112 
change is derived either by a mean change response (MCR) or a receiver operating characteristic 113 
(ROC) analysis. MCR compares the means of individuals indicating improvement on the anchor 114 




to those who do not report improvement. ROC provides a similar comparison based on the 115 
proportion of agreement between the MOI and the anchor. ROC analysis yields sensitivity, 116 
specificity, and accuracy statistics, similar to evaluation of diagnostic procedures or of other 117 
types of classification analyses. 118 
Early descriptions recommended using multiple methods t  determine the MCID and 119 
then “triangulating” on the best value.4-5 However, a specific or systematic method for this 120 
triangulation has not been suggested. Subsequently, methodologists have favored an anchor-121 
based approach and emphasized the importance of representing the perspective of the person 122 
served in determining meaningful change.3-5,9 123 
Studies attempting to identify the MCID for various measures have used a wide variety of 124 
methods. In their review, Engel and colleagues9 describe the methods used and found that only 125 
about half used an anchor-based approach. In practice, a distribution-based value in the 126 
neighborhood of ½ SD has typically been identified as the MCID and has been recommended for 127 
use in the absence of an empirically established value.5-6 We will not comprehensively review 128 
this literature; the interested reader is referred to recent reviews8-9 and other papers cited 129 
previously for more detailed information about the m thods and history of the MCID. In this 130 
commentary, we describe a method for systematically “triangulating” on the most appropriate 131 
value for the MCID using both distribution-based and chor-based approaches. We have used a 132 
similar method previously.10 In this paper, we present this method systematically and add 133 
additional reliability tests. We believe the method described here is appropriate for use with 134 
many standard rehabilitation measures and suggest that the use of a consistent method to derive 135 
MCIDs in rehabilitation will support communication about and comparability across studies. We 136 
have previously suggested that an indicator of a substantial improvement in status, the Robust 137 




Clinically Important Difference (RCID), might also be determined to identify cases in which 138 
change is not only minimally meaningful but impressive.11 The method described here 139 
systematically identifies values both for the MCID and RCID. 140 
Method 141 
The proposed method for systematically identifying the value of the MCID is 142 
fundamentally an anchor-based method. We agree with others cited previously that an anchor-143 
based method is preferable to using distribution-based indicators alone. However, we also 144 
believe that distribution-based indicators provide familiar and well-accepted benchmarks for 145 
evaluating measurement error and effect size. Consequently, initial steps in the proposed method 146 
determine a range of distribution-based indicators that are then further evaluated through anchor-147 
based procedures. 148 
The recommended distribution-based indicators are the standard error of measurement 149 
(SEM), the baseline (or pre-treatment) standard deviation (SD), and three factors of these basic 150 
indicators: ½SD, 1.96SEM, and the Reliable Change Id x (RCI). Their values range from the 151 
smallest amount of change that can be determined by the MOI (i.e., SEM) to very large change 152 
(i.e., 1 SD). 153 
We agree with Engel and colleagues9 that, when evaluating the proposed MCID in 154 
reference to an anchor, a ROC approach is preferable to a MCR approach. The MCR approach 155 
compares the mean change between those achieving the minimum amount of change 156 
(responders) and those who do not (non-responders), and consequently may not be sensitive to a 157 
minimally meaningful change among those responders whose change scores fall below the mean 158 
change. The method described below is a ROC approach. A ROC computation provides the 159 
sensitivity and specificity of the range of values of the MOI relative to the GIC. Accuracy can be 160 




computed by taking the weighted sum of sensitivity and specificity, with weights corresponding 161 
to proportion of individuals above and below the MCID (i.e., the prevalence). We also 162 
recommend computing Youden’s Index.12 By combining sensitivity and specificity, Youden’s 163 
Index provides an overall indicator of the performance of these metrics and, unlike the other 164 
more familiar indicators, is independent of the preval nce of responders and nonresponders. 165 
Youden’s Index can vary between 0 and 1 with higher values indicating a smaller overall 166 
proportion of false negatives and false positives. Definitions and formulas for these metrics are 167 
provided in Text Box 1. 168 
Since the validity of an anchor-based approach assume  that the anchor is representative 169 
of , that is, is associated with change on the MOI, the correlation between the anchor measure 170 
and change on the MOI is computed prior to any other computations. A Spearman correlation is 171 
suggested since most anchors, including the GIC recommended here, are ordinal measures. 172 
While a correlation of at least .3 to .35 has been r commended as a minimum correlation 173 
between the change score and the anchor,5 we suggest that a stronger correlation indicating at 174 
least 50% or better shared variance (i.e., correlation of .7 or higher) provides greater confidence 175 
that the anchor is sensitive to change on the MOI and that both these measures represent the 176 
same construct. 177 
The change in the MOI and the anchor may not be adequat ly correlated for a number of 178 
reasons. Most commonly, (a) the MOI change score does n t have adequate reliability or 179 
precision; (b) the time between measurements on the MOI is too great, leading to recall bias or 180 
response shift; or (c) the MOI is unreliable because of the participant’s impaired self-awareness. 181 
Lack of reliability or precision in the MOI and consequently MOI change can be avoided by 182 
carefully selecting statistically sound measures for evaluation. Measures with an interval level of 183 




scaling are required since, with such measures, the change score will indicate the same degree of 184 
change regardless of the initial level on the measure. Ordinal measures can be transformed to 185 
interval scaling through Rasch or other item-respone theory (IRT) procedures.  Recall bias is 186 
distortion in perceived change due to difficulty in recalling the progression of one’s condition 187 
over an extended period of time. An optimal period of time between initial and final 188 
measurement has not been well-defined and may vary with the MOI and the anchor.13 Response 189 
shift refers to a change in one’s perception of one’s condition over time. In other words, the 190 
factors that the rater considered in making the initial rating changed over the course of time and 191 
are different at the time of the final rating. Unreliability due to recall bias or response shift can 192 
probably not be addressed retrospectively and most likely prevents a valid MCID determination. 193 
Unreliability due to impaired self-awareness is also difficult to address retrospectively in 194 
participant ratings. In such cases, ratings made by a more objective observer are preferable for 195 
determining the MCID.  196 
If a lack of correlation between change in the MOI and the anchor prevents computation 197 
of the MCID, ½ SD may be used as the putative MCID, as recommended by others.5-6 198 
Alternatively, if a more conservative estimate of the clinically important difference is appropriate 199 
in the context of the research, the RCI may be used. This is the approach we used in prior work14 200 
in which a substantial correlation between change i the MOI and anchor was not obtained due 201 
to the extended time (5 years) between measurements of the MOI. Computing both these proxy 202 
values mirrors the derivation of a MCID and RCID. However, the use of such proxy values 203 
should only be used in specific research situations (e.g., the time between measurements is 204 
extremely long) where derivation of the MCID and RCID is not possible. Proxy values should 205 
not be substituted for systematic and precise derivation of the MCID and RCID in the long term. 206 





The basic steps for obtaining the MCID and RCID briefly are as follows: (1) obtain a 208 
representative sample (being aware that the MCID may vary among samples of varying severity 209 
of illness, chronicity, demographic, and other factors), (2) determine if the correlation between 210 
the MCID and the anchor is adequate to proceed (≥ 0.7), (3) compute the sensitivity, specificity, 211 
accuracy, and Youden’s Index for the MOI relative to the GIC in identifying those who indicate 212 
that their condition is “Better” or “Much Better”, and then (4) select the MCID and RCID 213 
corresponding to the highest accuracy and optimal sensitivity and specificity as indicated by 214 
Youden’s Index. A more detailed, step-by-step description of the method is provided as 215 
Supplementary Material 1. 216 
To demonstrate this method, we have constructed a mock data set (available as 217 
Supplemental Material 2) consisting of 100 cases. In this mock data set, the MOI was expressed 218 
as an integer (no decimal values) T-score between 0 and 100 with a mean of 50 and a SD of 10 at 219 
time 1. Reliability (r) was assumed to be 0.9. GIC values on an ordinal scale indicating much 220 
worse (-2), a little worse (-1), about the same (0), a little better (1), much better (2) were selected 221 
to generally agree with change on the MOI; however, to mirror reality, some values did not 222 
agree. The Spearman correlation between change on the MOI and the GIC was .88. With an 223 
adequate correlation between MOI change and the GIC (≥ 0.7), distribution-based indicators 224 
were calculated as follows: SEM=3.2; ½ SD=5.0; 1.96×SEM=6.2; RCI=8.8; 1 SD=10.0. 225 
Because the measure was integer-based, decimal values for the distribution-based indicators 226 
were rounded to the nearest whole integer as displayed in Tables 1-3. 227 
In this example, inspection of Table 1 shows both 1.96×SEM and .5 have the same 228 
accuracy and acceptable sensitivity and specificity. However, Youden’s Index favors .5 SD as 229 




the MCID. Inspection of Table 2 suggests the RCI and 1 SD as possible values for the RCID; 230 
both show good accuracy, sensitivity and specificity. However, RCI has a slightly higher 231 
Youden’s Index and is selected as the potential RCID. These proposed values are then evaluated 232 
for the entire sample (Table 3). Inspection of Table 3 shows that both the proposed MCID and 233 
RCID continue to perform well for the entire sample and are selected as the final MCID and 234 
RCID.  235 
Concluding Comments 236 
 Determination of the MCID for statistically reliable measures used in rehabilitation has 237 
significant potential value as described in the introduction to this paper. In contrast to effect size, 238 
the MCID is expressed in the units of the measure itself rather than referenced to the variability 239 
of its distribution and represents the smallest change that is clinically significant and meaningful 240 
to the person served. As such, the MCID for a measur  may vary across different populations 241 
(e.g., diagnostic groups) as well as with severity, chronicity, demographic and other factors 242 
within these populations. Effect size represents the magnitude of change between or within 243 
treatment groups and is not indicative of individual treatment response. Whereas, the MCID 244 
represents a degree of change that will be perceived as meaningful by most persons served and 245 
can be used to inform individual treatment decision.  246 
Measures developed using IRT should be used in deriving the MCID since they are 247 
reliable and are equivalent to interval measures in providing change scores of consistent value 248 
regardless of the initial level of the measure. While the impression of the treatment recipient is of 249 
paramount importance in determining whether a meaningful change has been obtained, the 250 
impression of a more objective observer is also of value, particularly in assessments in which 251 
there is substantial risk of impaired self-awareness on the part of the treatment recipient. The 252 




method described here focused on the evaluation of positive change since this is most often of 253 
interest in evaluating rehabilitation interventions. However, a similar method might also be used 254 
to evaluate negative change or deterioration. We attempted to provide a clear and straightforward 255 
approach to determining the MCID. Nonetheless, as shown in our example, reliability indicators 256 
for potential values may be very similar and some judgement may be required in the final 257 
determination. 258 
We proposed the determination of a RCID in addition o the MCID. However, we wish to 259 
emphasize the value of determining the minimal change that is meaningful to participants and 260 
providers, and to caution against the ascendance of the RCID as a more important indicator. The 261 
RCID is of interest only in identifying those who had an outstanding response to treatment. In 262 
some fields, the RCI is embraced as the premier measur  of significant change. However, while 263 
the RCI indicates a value that is very unlikely to occur by statistical chance, it does not address 264 
the issue of meaningful change since it is derived from a distribution-based approach. As 265 
described in MCID reviews and studies cited previously, participants may reliably perceive a 266 
meaningful change at a level much less than the RCI.267 
As investigations of methods for personalized medicine expand, both the MCID and 268 
RCID should be useful in characterizing individuals who benefit from specific treatments. On the 269 
historic timeline for the development of scientific methods (which can span a century), the 270 
MCID—first proposed 30 years ago—is just reaching adolescence. Consequently, further 271 
evolution of this concept and methodologies can be expected. For example, the best method to 272 
compute the standard error used in the calculation of some distribution-based indicators is 273 
debated,15 as can be the optimal measure for reliability. We have proposed that the correlation 274 
between the MOI and the anchor should be relatively strong, i.e, .7  or higher, while others5 have 275 




suggested a correlation as low as .3. Future systematic empirical investigation is required to 276 
determine the recommended correlation between the MOI and the anchor. In the interim, 277 
adaptation of a consistent approach to determining the MCID in rehabilitation will support 278 
clearer communications and comparison of results among rehabilitation providers and 279 
researchers. 280 
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Table 1. Agreement between distribution-based indicators and 
classification values of GIC = Better vs. No Change, Worse or Much 
Worse. 
 Accuracy Sensitivity Specificity Youden’s 
Index 
SEM=3 .74 1.00 .62 .62 
.5SD=5 .80 .88 .76 .64 
1.96SEM=6 .80 .77 .81 .58 
RCI=9 .79 .42 .95 .37 
1SD=10 .77 .31 .98 .29 
 
Table 2. Agreement between distribution-based indicators and 
classification values of GIC = Much Better vs. No Change, Worse or 
Much Worse. 
 Accuracy Sensitivity Specificity Youden’s 
Index 
SEM=3 .70 1.00 .62 .62 
.5SD=5 .81 1.00 .76 .76 
1.96SEM=6 .85 1.00 .81 .81 
RCI=9 .96 1.00 .95 .95 
1SD=10 .97 .94 .98 .92 
 
Table 3. Agreement between distribution-based indicators and 
classification values of GIC = Better or Much Better vs. No Change, 
Worse or Much Worse. 
 Accuracy Sensitivity Specificity Youden’s 
Index 
SEM=3 .78 1.00 .62 .62 
.5SD=5 .83 .93 .76 .69 
1.96SEM=6 .83 .86 .81 .67 
RCI=9 .82 .64 .95 .59 
1SD=10 .80 .55 .98 .53 
 
Supplementary Material 1: Detailed Steps for MCID and RCID Determination 
1. Obtain a representative sample, i.e., large as possible to represent the relevant patient group. 
Note: The Minimal Clinically Important Difference (MCID) may vary by severity, chronicity, 
demographic and other factors. 
2. Obtain pre-post measurements on the measure of interest (MOI) and compute change scores. 
3. At the time of the post-treatment ratings on the MOI, also obtain ratings of overall improvement 
relative to pre-treatment on a 5-point scale Global Impression of Change scale (GIC) from 
participants and providers, i.e., (-2) Much Worse, (-1) Worse, (0) No Change, (+1) Better, (+2) 
Much Better. 
4. Compute Spearman correlation coefficient between GIC and MOI change score; value > .5 may be 
acceptable; >.7, preferred. 
5. Compute distribution-based indicators for scale of interest: 
a. SEM = SDbaseline(√1 − ) 
b. ½ baseline (pre-treatment) SD 
c. 1.96 × SEM 
d. Reliable Change Index (RCI) = 1.96 × (SDbaseline(√2(1 − )) = 2.77 × SEM 
e. 1 SD (baseline) 
Note: In the above formulas, r = a measure of reliability, e.g., test-retest, Cronbach’s alpha, or 
for Rasch or IRT measures, person reliability. 
6. Divide the sample between those indicating “Better” on GIC and those indicating No Change, 
Worse, or Much Worse; do not include those indicating Much Better. 
7. With this dichotomized GIC as the classification value, compute sensitivity, specificity, accuracy, 
and Youden’s Index for the MOI change score at each level of the distribution-based indicators, 
comparing those at or above the distribution-based indicator to those with change scores below the 
indicator. 
8. Select the distribution-based indicator with the highest accuracy and optimal sensitivity and 
specificity as indicated by Youden’s Index as the proposed MCID. 
9. Repeat steps 6-7 dividing sample between those indicating Much Better and those indicating No 
Change, Worse, or Much Worse; do not include those indicating Better. 
10. Select the distribution-based indicator with the highest accuracy and optimal sensitivity and 
specificity as indicated by Youden’s Index as the proposed Robust Clinically Important Difference 
(RCID). 
11. Repeat steps 6-7 dividing sample between those indicating Better or Much Better and those 
indicating No Change, Worse, or Much Worse. 
12. Verify or reconsider MCID and RCID values based on results obtained in #11. 
For the sake of brevity, we will only describe the calculation of the first row in Table 2 in the 
main paper. To make these computations, the sample was divided into those whose MOI change was 3 
or more, i.e., a SEM, and those with change less than 3. These were compared to those whose GIC was 1 
(Better) and whose GIC was 0 or less (No Change, Worse, Much Worse). As described in Step 6, those 
with a GIC of 2 (Much Better) were not included. The Table below displays the numbers in each of 
these categories. Applying the formulas in Table 1, Accuracy = (36+26)/84 = 62/84 = .74; Sensitivity = 
26/(26+0) = 1.00; Specificity = 36/(36+22) = 36/58 = .62; and Youden’s Index = 1.00+.62-1 = .62. All 
the other rows in in Table 2-4 can be derived in the same fashion. 
Case distribution by GIC and Change of 1 SEM on MOI. 
 GIC ≤ 0 GIC = 1  












 58 26 84 
 
Text Box 1. Definitions and formulas. 
Sensitivity [percent of those improved on the GIC correctly identified by selected cutpoint on  
MOI change score]  = # True Positives / [# True Positives + # False Negatives] 
Specificity [percent of those not improved on the GIC correctly identified by selected cutpoint on  
MOI change score]  = # True Negatives / [# True Negatives + # False Positives] 
Accuracy [overall correct classification rate] = [# True Positives + # True Negatives] / # Total  
Youden’s Index =  Sensitivity + Specificity – 1.00 
 
